Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis

Journal of Drugs in Dermatology

Volumn 12, Issue 3, 2013, Pages

  Tan, Xi ^a   Feldman, Steven R ^b   Balkrishnan, Rajesh ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ARTICLE; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CONTROL GROUP; FOLLOW UP; HEPATITIS B; HEPATITIS C; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LUNG TUBERCULOSIS; PSORIASIS; RISK BENEFIT ANALYSIS; SYSTEMIC MYCOSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; INFECTION; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874592920     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Feldman SR. Epidemiology, pathophysiology, clinical manifestations, and diagnosis of psoriasis. In: Basow DS, ed. UpToDate. Waltham, MA: UpToDate, Inc; 2011.
2. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3(2):121-128. (Pubitemid 38832741)
3. Lebwohl M. Psoriasis. Lancet. 2003;361(9364):1197-1204.
4. Lima XT, Seidler EM, Lima HC, Kimball AB. Long-term safety of biologics in dermatology. Dermatol Ther. 2009;22(1):2-21.
5. Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035-1050.
6. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti- TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006:295(19):2275-2285. (Pubitemid 43736578)
7. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009:68(7):1136-1145.
8. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(7):889-894.
9. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010;39(5):327-346.
10. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403-3412. (Pubitemid 41612206)
11. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP, et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008;83(2):181-194. (Pubitemid 351303102)
12. Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-α antagonists. Pharmacotherapy. 2005;25(9):1181-1192. (Pubitemid 41242578)
13. Langley RG, Strober BE, Gu Y, Rozzo SJ, Okun MM. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol. 2010;162(6):1349-1358.
14. What is a serious adverse event? http://www.fda.gov/safety/medwatch/ howtoreport/ucm053087.htm. Accessed January 26, 2013.
15. HUMIRA (adalimumab) Injection [package insert]. North Chicago, IL: Abbott Laboratories; 2002.
16. Remicade (infliximab) [package insert]. Horsham, PA: Janssen Biotech Inc; 1998.
17. Enbrel (etanercept) for Subcutaneous Injection [package insert]. Thousand Oaks, CA: Immunex Corporation, Amgen Inc and Pfizer Inc; 1998.
18. Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59(2):209-217.
19. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3(3):148-155. (Pubitemid 36278124)
20. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis. 2004;39(8):1254-1255. (Pubitemid 40169331)
21. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261-1265. (Pubitemid 38608568)
22. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60(7):1884-1894.
23. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004;63(suppl 2):ii18-ii24. (Pubitemid 39424653)
24. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-α antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol. 2008;159(6):1217-1228.
25. Zein NN; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42(3):315-322. (Pubitemid 40254244)
26. Walker RE, Spooner KM, Kelly G, et al. Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis. 1996;174(1):63-68. (Pubitemid 26255555)
27. Sha BE, Valdez H, Gelman RS, et al. Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses. 2002;18(9):661-665. (Pubitemid 35356586)
28. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534-542. (Pubitemid 39278071)
29. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367-1374. (Pubitemid 41443403)
30. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1-31. e15.
31. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598-606. (Pubitemid 44436647)
32. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558-566. (Pubitemid 351239154)
33. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-115. (Pubitemid 350298146)
34. Asahina A, Nakagawa H, Etoh T, Ohtsuki M; Adalimumab M04-688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol. 2010;37(4):299-310.
35. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014-2022. (Pubitemid 37448924)
36. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304-1312. (Pubitemid 40933433)
37. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143(6):719-726. (Pubitemid 46955730)
38. Van de Kerkhof PCM, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-tosevere plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol. 2008;159(5):1177-1185.
39. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56(9):2896-2904. (Pubitemid 47502735)
40. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159(2):274-285. (Pubitemid 352009861)
41. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362(2):118-128.
42. Kircik LH, Del Rosso JQ. Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol. 2009;8(6):546-559.